$3 billion variety! Koren Pharmaceuticals" Engele Net is about to be approved.

On August 7th, Colum pharmaceutical industry submitted four types of generic Ingley net tablet listing application into the "in the approval" stage, is expected to be approved in the near future to become the second domestic after Howson after the drug listed manufacturers.
Ingley Net, a sodium-glucose co-transport protein 2 (SGLT-2) inhibitor developed by Burglinger Ingelheim, was approved by the FDA in August 2014 for use in people with type 2 diabetes.
December 2016, Engele's new adaptation to reduce the risk of cardiovascular death in adults with type 2 diabetes with cardiovascular disease was approved by the FDA, the first sugar-lowering drug to be shown to have cardiovascular benefits.
2019, Engele's net global sales exceed $3 billion.
According to the Pharmaceutical Rubik's Cube database, a total of eight SGLT-2 inhibitors are currently approved for listing worldwide, of which Caglie Net (Johnson and Johnson), Dagley Net (AstraZeneca), Englie Net (Blinger Ingelheim/Lilly) and Aglinger Net (Mercarton) have all been approved for listing in China, and the top three have all been negotiated for inclusion in the 2019 National Health Insurance Category B catalogue.
source: NextPharmahausen Pharmaceuticals Engele Net Imitation Has been approved for sale on July 30, and Colum Pharmaceuticals is expected to become the country's second manufacturer of the drug.
the current domestic application for the listing of Engele net generic drugs manufacturers are Zheng Datianqing, Wanbang Biochemicals and Osaikang and other 5.
.